Houston heart failure expert Dr. Biykem Bozkurt saw the new DIG analysis as part of this decade-long rehabilitation effort. The new analysis "is a call for the reexamination of digoxin in acute heart failure," she said as an ACC panelist who discussed the study.
Digoxin’s proponents seem to recognize their big challenge: A large, new study of dioxin on top of today’s standard treatments is the key to convincing skeptical colleagues, but who will pay for it? "The problem with digoxin is that no company sponsors it," Dr. Gheorghiade said.
Twitter @mitchelzoler